Principal Financial Group Inc. Sells 1,433 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Principal Financial Group Inc. lowered its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 1.1% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 134,827 shares of the biotechnology company’s stock after selling 1,433 shares during the quarter. Principal Financial Group Inc. owned about 0.06% of ADMA Biologics worth $1,507,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Viewpoint Capital Management LLC raised its stake in shares of ADMA Biologics by 18.6% during the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 2,416 shares in the last quarter. Eagle Asset Management Inc. boosted its position in shares of ADMA Biologics by 20.2% during the fourth quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 4,367 shares during the last quarter. CWM LLC lifted its position in ADMA Biologics by 114.2% during the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 4,367 shares during the period. ProShare Advisors LLC lifted its holdings in shares of ADMA Biologics by 9.2% during the 1st quarter. ProShare Advisors LLC now owns 54,293 shares of the biotechnology company’s stock valued at $358,000 after buying an additional 4,570 shares during the period. Finally, EntryPoint Capital LLC bought a new position in shares of ADMA Biologics in the 1st quarter worth approximately $31,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Up 4.4 %

NASDAQ ADMA opened at $17.65 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. The business has a fifty day moving average price of $14.81 and a 200 day moving average price of $10.31. ADMA Biologics, Inc. has a one year low of $3.06 and a one year high of $19.34. The company has a market cap of $4.09 billion, a P/E ratio of -887.50 and a beta of 0.61.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The business’s quarterly revenue was up 78.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.02) earnings per share. Research analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current fiscal year.

Insiders Place Their Bets

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Jerrold B. Grossman sold 136,861 shares of the stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the sale, the director now owns 467,305 shares of the company’s stock, valued at $8,070,357.35. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Mizuho increased their price objective on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. HC Wainwright increased their price target on shares of ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald lifted their price target on shares of ADMA Biologics from $15.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $15.50.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.